{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:00:35Z","timestamp":1760385635717,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dalbavancin is a new semisynthetic lipoglycopeptide with improved antimicrobial activity against various gram-positive pathogens. It demonstrates an extensive plasma half-life which permits outpatient parenteral antimicrobial therapy with weekly intervals and might therefore be an excellent treatment alternative for patients requiring prolonged antimicrobial therapy. The present study investigated dalbavancin monotherapy in an experimental implant-related methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) osteomyelitis model. A clinical MRSA isolate and a Kirschner-wire were inserted into the proximal tibia of anaesthetized Sprague-Dawley rats. Four weeks after infection 34 animals were treated over 4 weeks with either dalbavancin (20\u2009mg\/kg loading-dose; 10\u2009mg\/kg daily), vancomycin (50\u2009mg\/kg twice daily) or left untreated. Twenty-four hours after the last treatment dose tibial bones and Kirschner-wires were harvested for microbiological examination. Based on quantitative bacterial cultures of osseous tissue, dalbavancin was as effective as vancomycin and both were superior to no treatment. No emergence of an induced glycopeptide-\/lipoglycopeptide- resistance was observed after a treatment period of four weeks with either dalbavancin or vancomycin. In conclusion, monotherapy with dalbavancin was shown to be as effective as vancomycin for treatment of experimental implant-related MRSA osteomyelitis in rats, but both antimicrobials demonstrated only limited efficacy. Further studies are warranted to evaluate the clinical efficacy of dalbavancin for the treatment of periprosthetic <jats:italic>S. aureus<\/jats:italic> infections.<\/jats:p>","DOI":"10.1038\/s41598-018-28006-8","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T14:01:02Z","timestamp":1529416862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8149-6655","authenticated-orcid":false,"given":"Manuel","family":"Kussmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Obermueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Berndl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Reischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luzia","family":"Veletzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Burgmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Poeppl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"28006_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pid.2014.12.005","volume":"7","author":"P Vaidya","year":"2015","unstructured":"Vaidya, P., Pawar, G. & Krishnamurthy, N. Community acquired MRSA infections\u2014Three recent cases and an overview of CA MRSA infections. Pediatr. Infect. Dis. 7, 8\u201312 (2015).","journal-title":"Pediatr. Infect. Dis."},{"key":"28006_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0140-6736(14)61798-0","volume":"387","author":"BH Kapadia","year":"2016","unstructured":"Kapadia, B. H. et al. Periprosthetic joint infection. Lancet 387, 386\u2013394 (2016).","journal-title":"Lancet"},{"key":"28006_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.5301\/ijao.5000052","volume":"34","author":"L Montanaro","year":"2011","unstructured":"Montanaro, L. et al. Emerging pathogenetic mechanisms of the implant-related osteomyelitis by Staphylococcus aureus. Int. J. Artif. Organs. 34, 781\u2013788 (2011).","journal-title":"Int. J. Artif. Organs."},{"key":"28006_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","volume":"48","author":"A Leighton","year":"2004","unstructured":"Leighton, A. et al. Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers. Antimicrob. Agents Chemother. 48, 940\u20135 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"28006_CR5","doi-asserted-by":"publisher","first-page":"ii31","DOI":"10.1093\/jac\/dki006","volume":"55","author":"M Cavaleri","year":"2005","unstructured":"Cavaleri, M. et al. Pharmacokinetics and excretion of dalbavancin in the rat. J. Antimicrob. Chemother. 55, ii31\u201335 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"28006_CR6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0091270005280378","volume":"45","author":"M Buckwalter","year":"2005","unstructured":"Buckwalter, M. & Dowell, J. A. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J. Clin. Pharmacol. 45, 1279\u20131287 (2005).","journal-title":"J. Clin. Pharmacol."},{"key":"28006_CR7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","volume":"61","author":"AY Chen","year":"2007","unstructured":"Chen, A. Y., Zervos, M. J. & Vazquez, J. A. Dalbavancin: a novel antimicrobial. Int. J. Clin. Pract. 61, 853\u2013863 (2007).","journal-title":"Int. J. Clin. Pract."},{"key":"28006_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1302\/2058-5241.1.000037","volume":"1","author":"TF Moriarty","year":"2016","unstructured":"Moriarty, T. F. et al. Orthopaedic device-related infection: current and future interventions for improved prevention and treatment. EFORT Open Rev. 1, 89\u201399 (2016).","journal-title":"EFORT Open Rev."},{"key":"28006_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/joim.12233","volume":"276","author":"W Zimmerli","year":"2014","unstructured":"Zimmerli, W. Clinical presentation and treatment of orthopaedic implant-associated infection. J. Intern. Med. 276, 111\u2013119 (2014).","journal-title":"J. Intern. Med."},{"key":"28006_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/jac\/dkv357","volume":"71","author":"Y Barnea","year":"2016","unstructured":"Barnea, Y. et al. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. J. Antimicrob. Chemother. 71, 460\u2013463 (2016).","journal-title":"J. Antimicrob. Chemother."},{"doi-asserted-by":"crossref","unstructured":"Reffuveille, F., Josse, J., Vall\u00e9, Q., Gangloff, C. M. & Gangloff S. C. Staphylococcus aureus Biofilms and their Impact on the Medical Field, http:\/\/www.intechopen.com\/books\/the-rise-of-virulence-and-antibiotic-resistance-in-staphylococcus-aureus\/staphylococcus-aureus-biofilms-and-their-impact-on-the-medical-field (2017).","key":"28006_CR11","DOI":"10.5772\/66380"},{"key":"28006_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.diagmicrobio.2016.05.009","volume":"85","author":"J Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez, J., Greenwood-Quaintance, K. E. & Patel, R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Diagn. Microbiol. Infect. Dis. 85, 449\u2013451 (2016).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"28006_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ijos.2014.65","volume":"7","author":"H Wu","year":"2015","unstructured":"Wu, H., Moser, C., Wang, H. Z., H\u00f8iby, N. & Song, Z. J. Strategies for combating bacterial biofilm infections. Int. J. Oral Sci. 7, 1\u20137 (2015).","journal-title":"Int. J. Oral Sci."},{"key":"28006_CR14","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1128\/AAC.02720-13","volume":"58","author":"W Poeppl","year":"2014","unstructured":"Poeppl, W. et al. Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats. Antimicrob. Agents Chemother. 58, 5111\u20135116 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"28006_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/AAC.04246-14","volume":"59","author":"T Lingscheid","year":"2015","unstructured":"Lingscheid, T. et al. Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats. Antimicrob. Agents Chemother. 59, 859\u201363 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"28006_CR16","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne, M. W. et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob. Agents Chemother. 59, 1849\u20131855 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"28006_CR17","doi-asserted-by":"publisher","first-page":"ii21","DOI":"10.1093\/jac\/dki007","volume":"55","author":"S Lopez","year":"2005","unstructured":"Lopez, S. et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J. Antimicrob. Chemother. 55, ii21\u201324 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"28006_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00132-015-3184-y","volume":"44","author":"W Zimmerli","year":"2015","unstructured":"Zimmerli, W. Orthopaedic implant-associated infections: Update of antimicrobial therapy. Orthopade. 44, 961\u2013966 (2015).","journal-title":"Orthopade."},{"doi-asserted-by":"publisher","unstructured":"Koeth, L. M., DiFranco-Fisher, J. M. & McCurdy, S. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically. J. Vis. Exp. https:\/\/doi.org\/10.3791\/53028 (2015).","key":"28006_CR19","DOI":"10.3791\/53028"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28006-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:44:16Z","timestamp":1671605056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28006-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["28006"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-28006-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"9 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9661"}}